Dave Licata

Dave Licata is a Stanford-trained mechanical engineer turned biotech operator who co-founded TORL BioTherapeutics with legendary UCLA oncologist Dennis Slamon. As President and CFO (and founding CEO), he built TORL into a clinical-stage oncology company developing antibody-drug conjugates against targets like Claudin 6 and Claudin 18.2, raising more than $450 million while keeping a reputation for capital efficiency. He is also Executive Chairman of 1200 Pharma and previously founded Holoclara and served as an Entrepreneur in Residence at Caltech.